Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharma (NQ: INO )

9.850 -0.310 (-3.05%)
Streaming Delayed Price Updated: 11:37 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inovio Pharma

< Previous 1 2 3 4 5 6 7 8 Next >
Why Inovio Pharmaceuticals Stock Is Popping Off
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher by 9.11% to $2.34 after the company reported third-quarter financi 
Via Benzinga
Inovio Pharmaceuticals (INO) Q3 2022 Earnings Call Transcript
INO earnings call for the period ending September 30, 2022. 
Via The Motley Fool
What's Going On With Inovio Pharmaceuticals Stock Tuesday After Hours
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading marginally lower by 0.93% to $2.12 after the company reported  
Via Benzinga
Threats For New Outbreak Looms, As Scientists Signal Deadly Monkeypox Variant Circulating In Central Africa
Researchers have warned that a dangerous monkeypox variant with a fatality rate as high as 10% is circulating in Central Africa, which could trigger new global outbreaks. After analyzing 1,463 cases... 
Via Benzinga
Why Inovio Pharmaceuticals Stock Zoomed Nearly 6% Higher Today
The biotech is ceasing its internally funded efforts to develop a heterologous coronavirus booster. 
Via The Motley Fool
Why Inovio Pharmaceuticals' Shares Jumped 17.31% on Monday
The stock jumped Monday despite no news from the company. 
Via The Motley Fool
Inovio Pharma Highlights Early Data From Experimental Drug For Respiratory Tract Disease
Via Benzinga
RBC Capital Lowers Inovio Price Target As It Awaits This
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Inovio Pharma Stops Work On INO-4800 As COVID-19 Heterologous Booster
Via Benzinga
Philips, Owens & Minor And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Inovio Lays Out Corporate Reorganization To Extend Cash Runway Into 2024
Via Benzinga
Why Inovio Pharmaceuticals Stock Is Rising Today
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher Monday amid increasing monkeypox concerns. 
Via Benzinga
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case. 
Via Benzinga
Tesla, Credit Suisse And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded mixed this morning after recording losses for the third quarter. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Is Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has Slowed
Via Benzinga
Recap: Inovio Pharmaceuticals Q2 Earnings
  Inovio Pharmaceuticals (NASDAQ:INO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS. 
Via Benzinga
Two Appealing Biotech Stocks for Two Distinct investors
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Does Amarin Deserve a Spot in Your Portfolio after Earnings ?
Amarin recently announced its earnings for Q2'22 with mixed results. Here we'll examine the pros and cons of having this penny stock in your portfolio. 
Via MarketBeat
Topics Earnings
Exposures Financial
Monkeypox Stocks On The Move: What Investors Should Know About The Outbreak
The World Health Organization has declared the 2022 outbreak of monkeypox a global health emergency. The monkeypox crisis isn't as severe as the COVID-19 pandemic, but it has a number of health care... 
Via Benzinga
Monkeypox A Nationally Notifiable Condition, CDC Poised To Announce: Report
Via Benzinga
Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022. 
Via Benzinga
7 Monkeypox Stocks That May Take Off in Q2
SIGA Technologies (SIGA) may lead on the list of Monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. 
Via InvestorPlace
This Communication Services Stock Is Trading Higher By Over 82%, Here Are 45 Stocks Moving In Wednesday's Mid-Day Session
Gainers Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares surged 82.2% to $2.6787. Direct Digital Holdings said its supply-side advertising platform, Colossus SSP, reported a 540% year-over-year... 
Via Benzinga
7 Monkeypox Stocks to Watch Right Now
Wondering what are the best monkeypox stocks to watch? Here are the companies producing vaccines to help fight the spread of the virus. 
Via InvestorPlace
Morning Brief: Top Financial Stories Dominating on Tuesday, May 24
CNBC 
Via Benzinga
WHO Says Monkeypox Outbreak 'Unusual' But 'Containable'
The World Health Organization (WHO) said that there had been 131 confirmed monkeypox cases and 106 further suspected cases, 
Via Benzinga
24 Stocks Moving in Monday's Pre-Market Session
Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on Friday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.